144 related articles for article (PubMed ID: 2201824)
1. Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
Degos L
Leuk Res; 1990; 14(8):731-3. PubMed ID: 2201824
[TBL] [Abstract][Full Text] [Related]
2. Differentiating agents in the treatment of leukemia.
Degos L
Leuk Res; 1990; 14(8):717-9. PubMed ID: 2201823
[TBL] [Abstract][Full Text] [Related]
3. Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible?
Januszewicz EH; Firkin FC
Aust N Z J Med; 1988 Aug; 18(5):705-11. PubMed ID: 3072952
[TBL] [Abstract][Full Text] [Related]
4. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
[No Abstract] [Full Text] [Related]
5. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
[TBL] [Abstract][Full Text] [Related]
6. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
[TBL] [Abstract][Full Text] [Related]
7. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of myelodysplasia/acute myeloid leukemia 'on therapy' in two patients with acute promyelocytic leukemia.
Chelghoum Y; Plesa A; Ducastelle S; Elhamri M; Thomas X
Indian J Cancer; 2016; 53(1):59-60. PubMed ID: 27146742
[No Abstract] [Full Text] [Related]
10. [All-trans-retinoic acid in differentiation therapy of hemo-cytopathic proliferative diseases. II. Retinoids in clinical practice].
Skotnicki AB; Sledziowski P; Sacha T; Jurczak W
Przegl Lek; 1995; 52(4):145-6. PubMed ID: 7638362
[No Abstract] [Full Text] [Related]
11. Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes.
Hellström E; Robèrt KH; Soppi E; Ost A; Putkonen PO; Gahrton G
Leuk Res; 1989; 13(12):1113-21. PubMed ID: 2615468
[TBL] [Abstract][Full Text] [Related]
12. The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia.
Fontana JA; Rogers JS; Durham JP
Cancer; 1986 Jan; 57(2):209-17. PubMed ID: 3455835
[TBL] [Abstract][Full Text] [Related]
13. [A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
Maruta A; Miyashita H; Kodama F; Harano H; Kanamori H; Takahashi K; Noguchi T; Matsuzaki M; Ogawa K; Motomura S
Rinsho Ketsueki; 1988 Jan; 29(1):8-13. PubMed ID: 3385938
[No Abstract] [Full Text] [Related]
14. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.
Hellström E; Robèrt KH; Gahrton G; Mellstedt H; Lindemalm C; Einhorn S; Björkholm M; Grimfors G; Udén AM; Samuelsson J
Eur J Haematol; 1988 May; 40(5):449-59. PubMed ID: 3378598
[TBL] [Abstract][Full Text] [Related]
16. Use of differentiation-inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia.
Hoffman SJ; Robinson WA
Am J Hematol; 1988 Jun; 28(2):124-7. PubMed ID: 3293438
[TBL] [Abstract][Full Text] [Related]
17. [A new concept: treatment using differentiation of the malignant cell in man].
Degos L
Bull Acad Natl Med; 1995 Nov; 179(8):1689-700. PubMed ID: 8717185
[TBL] [Abstract][Full Text] [Related]
18. Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Heyll A; Aul C; Heyll U; Schneider W
Haematol Blood Transfus; 1987; 30():322-5. PubMed ID: 3476364
[No Abstract] [Full Text] [Related]
19. [Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases].
Huang ME; Ye YC; Zhao L
Zhonghua Nei Ke Za Zhi; 1987 Jun; 26(6):330-2, 380. PubMed ID: 3477416
[No Abstract] [Full Text] [Related]
20. Retinoic acid in mono- or combined differentiation therapy of myelodysplasia and acute promyelocytic leukemia.
Blazsek I; Farabos C; Musset M; Goldschmidt E; Comisso M; Benavides M; Wang ZY; Labat ML; Mathé G; Misset JL
Biomed Pharmacother; 1991; 45(4-5):169-77. PubMed ID: 1932600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
